MET inhibitor Compound 1

Research use only, not for human use.

A novel potent, selective orally bioavailable MET tyrosine kinase inhibitor with IC50 of <1 nM and 12 nM for unphosphorylated and phosphorylaed MET, respectively.

A novel potent, selective orally bioavailable MET tyrosine kinase inhibitor with IC50 of <1 nM and 12 nM for unphosphorylated and phosphorylaed MET, respectively; demonstrates potent, broad spectrum activity against MET mutants (V1110I, H1112Y, L1195V, Y1235D, D1228H and M1250T) with IC50 of <1 nM-57 nM, and Y1230 mutants with moderate potency (IC50=25-280 nM); displays >50-fold selectivity in a panel of 130 kinases with exception of Fms and TrkA/B/C; inhibits MET-dependent tumor cell growth in vivo through decreasing phosphorylaed MET.

——

——

——

Angiogenesis

c-Met/HGFR

c-Met/HGFR

——

——

1208248-23-0

449.426

C21H17F2N9O

>98% (HPLC)

——

——

N-(6-(difluoro(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)methyl)imidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxamide

(-20℃)

With Ice Pack

≥ 2 years